PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2148796
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 2148796
The global angioplasty balloons market size was valued at USD 2.97 billion in 2025. The market is projected to grow from USD 3.13 billion in 2026 to USD 4.81 billion by 2034, registering a CAGR of 5.5% during the forecast period from 2026 to 2034. North America dominated the global angioplasty balloons market in 2025, accounting for a 37.37% market share, supported by advanced healthcare infrastructure, increasing cardiovascular disease prevalence, high adoption of minimally invasive procedures, and the presence of major medical device manufacturers.
Angioplasty balloons are medical-grade inflatable devices attached to catheter systems and used during minimally invasive vascular procedures to open narrowed or blocked blood vessels. These devices help restore blood flow by dilating arteries and preparing vessels for stent placement or other interventions.
The increasing prevalence of coronary artery disease, peripheral artery disease, aging population, rising healthcare expenditure, and growing preference for minimally invasive cardiovascular procedures are driving market growth.
According to the Centers for Disease Control & Prevention (CDC), approximately 1 in 20 adults aged 20 years and older in the U.S. suffered from coronary artery disease in 2024, highlighting the growing need for cardiovascular intervention devices.
Major companies operating in the market include Medtronic, Boston Scientific Corporation, Abbott, BD, Koninklijke Philips N.V., B. Braun SE, Biosensors International Group, Meril, Cordis, and Lepu Medical Technology. These companies are focusing on advanced balloon catheter designs, drug-coated technologies, and strategic approvals to strengthen their market position.
Angioplasty Balloons Market Trends
Technological Advancements in Balloon Catheter Design
Innovation in balloon catheter technology is a major trend shaping the market. Manufacturers are developing advanced products such as drug-coated balloons, non-compliant balloons, high-pressure balloons, cutting balloons, scoring balloons, and perfusion balloons to improve lesion treatment and procedural outcomes.
Drug-coated balloons are gaining significant attention due to their ability to deliver antiproliferative drugs directly to vessel walls without leaving permanent implants. This "leave-nothing-behind" approach is increasingly preferred in coronary and peripheral interventions.
For instance, in June 2023, Surmodics Inc. received FDA approval for the SurVeil drug-coated balloon (DCB), strengthening adoption of advanced balloon technologies.
Market Dynamics
Market Drivers
Increasing Preference for Minimally Invasive Cardiovascular Procedures
The rising prevalence of cardiovascular diseases and increasing preference for minimally invasive treatments are major factors driving angioplasty balloons market growth.
Angioplasty procedures provide shorter recovery times, reduced hospitalization periods, and lower procedural risks compared with traditional surgical interventions. The increasing adoption of percutaneous coronary intervention (PCI) and peripheral vascular interventions is supporting product demand.
According to 2021 data published by Diagnostic and Interventional Cardiology, more than 965,000 angioplasty procedures are performed annually in the U.S.
Growing cath lab infrastructure, increasing healthcare expenditure, expanding physician training programs, and continuous product innovation are further supporting market growth.
Market Restraints
High Cost of Advanced Angioplasty Balloons
The high cost associated with advanced angioplasty balloons is a major challenge, especially in emerging economies and cost-sensitive healthcare systems.
Drug-coated balloons, cutting balloons, scoring balloons, and high-pressure balloons require advanced engineering, specialized coatings, clinical validation, and regulatory approvals, increasing their overall cost.
According to 2025 CMS statistics, the retail price of the AGENT Paclitaxel-Coated Balloon Catheter was approximately USD 5,500, limiting adoption in some healthcare settings.
Limited reimbursement coverage and procurement restrictions further impact market penetration.
Market Opportunities
Expansion of Cath Lab Infrastructure
The expansion of catheterization laboratory infrastructure in emerging economies is creating significant growth opportunities for angioplasty balloon manufacturers.
Increasing healthcare investments, rising cardiovascular disease burden, and government initiatives to improve access to cardiac care are encouraging installation of cath labs in hospitals and specialty centers.
For instance, Koninklijke Philips N.V. installed more than 1,500 cath labs in India by February 2024, supporting the expansion of interventional cardiac procedures.
Market Challenges
Limited Healthcare Access in Emerging Countries
Limited access to advanced healthcare facilities remains a major challenge for market growth. Many developing countries face issues related to healthcare affordability, reimbursement limitations, shortage of trained specialists, and inadequate availability of advanced medical devices.
According to World Bank data from 2023, approximately 4.5 billion people globally lack full access to essential health services, affecting adoption of advanced cardiovascular procedures.
By Product Type
The angioplasty balloons market is segmented into:
The standard balloons segment dominated the market in 2025 due to widespread use in angioplasty procedures, affordability, and availability across healthcare facilities.
The drug-coated balloons segment is expected to grow at a CAGR of 6.5% during 2026-2034, driven by increasing adoption of drug delivery technologies and preference for implant-free treatment approaches.
By Application
The market is segmented into:
The coronary artery disease segment dominated the market in 2025 with a 67.1% share due to increasing prevalence of coronary disorders and rising demand for angioplasty procedures.
The peripheral artery disease segment is expected to grow at a CAGR of 6.0% during the forecast period.
By Balloon Compliance
The market is categorized into:
The semi-compliant balloons segment dominated the market in 2025 with a 59.0% share due to increasing clinical adoption and use in vessel pre-dilatation procedures.
The compliant balloons segment is projected to grow at a CAGR of 3.9% during 2026-2034.
By End User
The market is divided into:
The hospitals & ASCs segment dominated the market in 2025 due to the increasing number of angioplasty procedures performed in hospital settings.
The segment is expected to hold 88.2% share in 2026.
North America
North America dominated the market in 2025 with a market value of USD 1.11 billion. Growth is supported by advanced healthcare infrastructure, increasing cardiovascular disease prevalence, rising PCI procedures, and strong presence of leading medical device companies.
The U.S. angioplasty balloons market is projected to reach approximately USD 1.03 billion in 2026.
Europe
Europe is expected to grow at a CAGR of 4.6% during 2026-2034 and is projected to reach USD 0.93 billion in 2026.
Growth is driven by increasing cardiovascular disease cases, adoption of drug-coated balloons, and advanced healthcare systems.
Germany is expected to reach approximately USD 0.22 billion in 2026, while the U.K. market is projected at USD 0.15 billion.
Asia Pacific
Asia Pacific is projected to reach USD 0.75 billion in 2026 due to increasing adoption of minimally invasive procedures, expanding healthcare infrastructure, and rising cardiovascular disease burden.
China's market is estimated at USD 0.26 billion in 2026, Japan at USD 0.18 billion, and India at USD 0.11 billion.
Latin America and Middle East & Africa
These regions are expected to witness moderate growth due to increasing healthcare investment, cardiovascular disease prevalence, and improving access to interventional procedures.
The GCC market is projected to reach USD 0.06 billion in 2026, while South Africa is expected to reach approximately USD 0.02 billion.
Competitive Landscape
The angioplasty balloons market is competitive, with companies focusing on technological innovation, regulatory approvals, and product portfolio expansion.
Key companies include:
Boston Scientific and Medtronic maintained strong market positions in 2025 due to diversified product portfolios and continuous investment in advanced balloon catheter technologies.
Key Industry Developments
Report Coverage
The angioplasty balloons market report provides comprehensive analysis of market size, forecast trends, drivers, restraints, opportunities, challenges, segmentation, regional outlook, technological advancements, competitive landscape, and key industry developments. The report highlights the impact of cardiovascular disease prevalence, minimally invasive procedure adoption, and innovation in balloon catheter technologies on future market growth.
Conclusion
The global angioplasty balloons market is expected to grow from USD 2.97 billion in 2025 to USD 4.81 billion by 2034, driven by increasing cardiovascular disease burden, rising adoption of minimally invasive procedures, expansion of cath lab infrastructure, and technological advancements in balloon catheter systems. Growth opportunities will emerge from drug-coated balloons and emerging healthcare markets. However, high device costs, reimbursement limitations, and competition from alternative cardiovascular technologies will remain key challenges during the forecast period.
Segmentation By Product Type, Application, Balloon Compliance, End User, and Region
By Product Type
By Application
By Balloon Compliance
By End User
By Region